Humacyte, Inc. (HUMA)

Humacyte's stock (HUMA) has experienced fluctuations, with a decline of 19.40% over the past year but a recent increase of 63.10% in the past month. Key events include a Nasdaq bid price non-compliance notice, Q4 and full-year 2025 financial results, realignment of ex-U.S. rights to Symvess, Israeli Ministry of Health acceptance of MAA for Symvess, a purchase commitment from Saudi Arabia, and a virtual KOL event.

Information detailing the seasonality of demand for Humacyte's products is not explicitly available. Early trends from the commercial launch of Symvess suggest a ramp-up in market penetration rather than a recurring seasonal pattern. Demand is likely driven more by medical necessity and ongoing clinical needs.

Humacyte, Inc. is a biotechnology company focused on developing and manufacturing universally implantable, bioengineered human tissues known as Human Acellular Vessels (HAVs), or Symvess. Symvess has received FDA approval for the treatment of extremity vascular trauma. HAVs are in late-stage clinical trials for arteriovenous (AV) access for hemodialysis and peripheral arterial disease (PAD). Preclinical development is underway for pediatric heart surgery, coronary artery bypass grafting (CABG), and cellular therapy delivery.

Humacyte, Inc. is headquartered in Durham, North Carolina, United States. The company is pursuing international expansion, with commercial initiatives and regulatory efforts underway in the Kingdom of Saudi Arabia and Israel.

Humacyte's reputation has been influenced by the FDA approval of Symvess and its commercial launch, a legal investigation following a securities class action lawsuit, and international expansion efforts in Israel and Saudi Arabia.

Humacyte's ownership structure includes institutional investors (16.06% to 44.71%), insiders (5.10% to 9.89%), and the general public/retail investors (46% to 74.05%). Fresenius Medical Care AG is a significant shareholder, holding around 9.5% to 14% of shares outstanding.